Versant Ventures

• Kevin L. Grove

Sources: doi.org

• Nouscom

  Series D

• Antag Therapeutics

  Venture, Lead, Dec 4, 2024

• LENZ Therapeutics

  Series B, Mar 7, 2023

• Lycia Therapeutics

  Series B, Sep 9, 2021

• Century Therapeutics

  Series C, Mar 3, 2021

• Vividion Therapeutics

  Series C, Feb 1, 2021

• Contineum Therapeutics

  Series C, $7M, Feb 1, 2021

• Monte Rosa Therapeutics

  Series B, Sep 25, 2020

• LENZ Therapeutics

  Series A, $30M, Jun 1, 2020

• Lycia Therapeutics

  Mar 3, 2020

• Repare Therapeutics

  Series B, Sep 4, 2019

• Vividion Therapeutics

  Series B, Apr 1, 2019

• Aprea Therapeutics

  Series C, $6.2M, Feb 1, 2019

• Akero Therapeutics

  Series B, $2.4M, Dec 1, 2018

• Akero Therapeutics

  Series A, $10.7M, Jun 1, 2018

• BlueRock Therapeutics

  Series A, Dec 12, 2016

• Aprea Therapeutics

  Series B, $13.8M, Mar 1, 2016

• Ocular Therapeutix

  Series D, $3.2M, Feb 1, 2011

Sources: globenewswire.com, pharmatimes.com, ir.lenz-tx.com, lyciatx.com, prnewswire.com, sec.gov, startupticker.ch, theglobeandmail.com, news.google.com

• Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression

  Consulting or advice, Fees or honoraria, Mar 12, 2026

Sources: pubmed.ncbi.nlm.nih.gov